Juno Therapeutics — Investor Presentation (January 2017)
18 slides from Juno Therapeutics's investor presentation, Jan 9, 2017
Slide 1: January 2017 Corporate Presentation
January 2017 Corporate Presentation Juno Therapeutics Proprietary Materials Exhibit 99.1
Slide 2: Forward-looking Statements, Investigational Status, and Interim Data
Juno Therapeutics 2 Proprietary Materials Forward-looking Statements, Investigational Status, and Interim Data This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize
Slide 3: Building the Leading T Cell Company
Juno Therapeutics 3 Proprietary Materials Building the Leading T Cell Company Progress with potential best-in-class CD19 product candidate and platform – JCAR017 on the market as early as 2018 – Significant advances in defining attributes that correlate with complete response in NHL – Year-end pro
Slide 4: Examples of Rapid Tumor Shrinkage in Clinical Trials
Juno Therapeutics 4 Proprietary Materials Examples of Rapid Tumor Shrinkage in Clinical Trials Day 29 After CD19 CAR T Cells NHL Patient Before CD19 CAR T Cells Day 33 After CD19 CAR T Cells CLL Patient Before CD19 CAR T Cells
Slide 5: Juno Strategy: Building the Category Leader
Juno Therapeutics 5 Proprietary Materials Combination Strategies: PD-L1 (ongoing) Ibrutinib (2017) A2aR (2017/2018) Others Juno Strategy: Building the Category Leader B-cell Malignancies Execute CD19 program: JCAR017 in NHL – approval as early as 2018 JCAR017 in CLL – approval as early a
Slide 6: JCAR015 Phase II ROCKET Trial Update
Juno Therapeutics 6 Proprietary Materials JCAR015 Phase II ROCKET Trial Update Clinical hold on November 22 38 total treated patients to date – 8 with flu/cy conditioning regimen – 3 treatment-related deaths – 30 with cy alone conditioning regimen – 2 treatment-related deaths – Early efficacy en
Slide 7: JCAR017: Building the CD19 Category Leader
Juno Therapeutics 7 Proprietary Materials JCAR015 JCAR017 Co-stimulatory domain CD28 4-1BB Cells T cells selected Defined composition (1:1 ratio of CD4 / CD8) Manufacturing Key steps automated and functionally closed Process design to deliver more naïve and quiescent cells Viral Vector Gamma Lenti J
Slide 8: 4-1BB versus CD28 CAR T Co-stimulatory Domain Matters
Juno Therapeutics 8 Proprietary Materials 4-1BB versus CD28 CAR T Co-stimulatory Domain Matters Increased persistence Increased central memory & naïve cells Metabolic profile supporting gradual, sustained expansion Decreased persistence Increased effector memory cells Metabolic profile s
Slide 9: The Type of CAR T Cell Matters
Juno Therapeutics 9 Proprietary Materials The Type of CAR T Cell Matters (1)Assumes body weight of 80 kg for adult NHL and 50 kg for pediatric ALL. (2) The dosing range for the trial is 100 - 500 million as a flat dose. (3)Total dose is dependent on body weight. Potency Disease Setting JCAR017 (tota
Slide 10: NHL: Potential Best-in-class Profile
Juno Therapeutics 10 Proprietary Materials Potential to differentiate on efficacy and safety NHL: Potential Best-in-class Profile Patient Characteristics Goal » JCAR017 NHL registration trial to initiate in 2017 with approval as early as 2018 Dose Level 1 5*107 N=19 – 22 Dose Level 2 1*108 N=2 ORR 1
Slide 11: Cell Persistence + Tolerability = Ability to Combine
Juno Therapeutics 11 Proprietary Materials Cell Persistence + Tolerability = Ability to Combine Phase I TRANSCEND: 3 of 4 patients that relapsed had persistent CAR T cells Case study demonstrates persistent CAR T cells can re-induce CR Complete Response at Day 29 25 20 15 5 0 0 30 60 90 120 150
Slide 12: Path to Next-Generation of Defined Cell Products
Juno Therapeutics 12 Proprietary Materials Path to Next-Generation of Defined Cell Products Epigenetic clustering (ATACseq) analysis points to clear product differences between responders versus non-responders. We can translate into cell physiology. responders non-responders
Slide 13: CLL Emerging as a Significant Opportunity
Juno Therapeutics 13 Proprietary Materials (1)All CLL patients have been previously treated with ibrutinib. There was 1 treatment-related death in 24 treated CLL patients to-date. Severe cytokine release syndrome = 8% (2 of 24 patients). Severe neurotoxicity = 25% (6 of 24 patients). For JCAR014, in
Slide 14: Expanding the Franchise into Multiple Myeloma
Juno Therapeutics 14 Proprietary Materials Expect BCMA CAR to enter the clinic in 1H2017 Expanding the Franchise into Multiple Myeloma Variable BCMA surface expression 3 Inadequate CAR T cell persistence 1 Complex tumor micro-environment 2 Multiple targets Binder selection Combinations Fully
Slide 15: Applying CARs & TCRs to Solid Organ Cancers
Juno Therapeutics 15 Proprietary Materials Applying CARs & TCRs to Solid Organ Cancers Heavily pretreated 50 year old male with right temporal GBM Clinical response for 7.5 months with no Grade 3 or higher events CAR T product candidate targeting IL13Rα2 Case Study: CAR T Therapy in GBM(1) (1)
Slide 16: Automation Lowers Cost and Improves Efficiency
Juno Therapeutics 16 Proprietary Materials Manual process High operating expenses ISO 5 staff: cost: $$$$ Closed and automated process Defined cell process ISO 7 / 8 staff: cost: $$$ Closed, automated, and integrated process 1-2 machines 2-4 day manufacturing time Cell se
Slide 17: Building Capabilities
Juno Therapeutics 17 Proprietary Materials • JuMP facility online • Closed & automated manufacturing • Defined cell product • Celgene collaboration – JCAR017 PRIME designation • JW Therapeutics – investment in China • Internal and BD opportunities • Translational medicine • $1.04 billion as of 3Q16
Slide 18: Robust and Diverse CAR & TCR Pipeline
Juno Therapeutics 18 Proprietary Materials Robust and Diverse CAR & TCR Pipeline Active Programs Description CD19: JCAR017 Pediatric ALL Phase I / II Adult NHL Phase I CD19: Combination with PD-L1 Adult NHL Phase I CD19: JCAR014 Adult B Cell Malignancies Phase I / II Exploratory Pathway (C
Juno Therapeutics — Investor Presentation (January 2017) on 6ix